1. Home
  2. KELYA vs NUVB Comparison

KELYA vs NUVB Comparison

Compare KELYA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KELYA
  • NUVB
  • Stock Information
  • Founded
  • KELYA 1946
  • NUVB 2018
  • Country
  • KELYA United States
  • NUVB United States
  • Employees
  • KELYA N/A
  • NUVB N/A
  • Industry
  • KELYA Professional Services
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • KELYA Consumer Discretionary
  • NUVB Health Care
  • Exchange
  • KELYA Nasdaq
  • NUVB Nasdaq
  • Market Cap
  • KELYA 752.3M
  • NUVB 850.3M
  • IPO Year
  • KELYA N/A
  • NUVB N/A
  • Fundamental
  • Price
  • KELYA $18.14
  • NUVB $2.63
  • Analyst Decision
  • KELYA Buy
  • NUVB Strong Buy
  • Analyst Count
  • KELYA 1
  • NUVB 6
  • Target Price
  • KELYA $29.00
  • NUVB $6.17
  • AVG Volume (30 Days)
  • KELYA 145.9K
  • NUVB 1.5M
  • Earning Date
  • KELYA 11-07-2024
  • NUVB 11-06-2024
  • Dividend Yield
  • KELYA 1.65%
  • NUVB N/A
  • EPS Growth
  • KELYA 5360.05
  • NUVB N/A
  • EPS
  • KELYA 1.16
  • NUVB N/A
  • Revenue
  • KELYA $4,372,900,000.00
  • NUVB $2,162,000.00
  • Revenue This Year
  • KELYA N/A
  • NUVB N/A
  • Revenue Next Year
  • KELYA $8.90
  • NUVB $13.99
  • P/E Ratio
  • KELYA $15.62
  • NUVB N/A
  • Revenue Growth
  • KELYA N/A
  • NUVB N/A
  • 52 Week Low
  • KELYA $18.07
  • NUVB $1.21
  • 52 Week High
  • KELYA $25.27
  • NUVB $4.16
  • Technical
  • Relative Strength Index (RSI)
  • KELYA 36.72
  • NUVB 55.93
  • Support Level
  • KELYA $19.85
  • NUVB $2.18
  • Resistance Level
  • KELYA $22.44
  • NUVB $2.37
  • Average True Range (ATR)
  • KELYA 0.53
  • NUVB 0.14
  • MACD
  • KELYA 0.01
  • NUVB 0.04
  • Stochastic Oscillator
  • KELYA 1.60
  • NUVB 87.80

About KELYA Kelly Services Inc.

Kelly Services Inc is a provider of workforce solutions and consulting and staffing services. The company's operations are divided into five business segments namely Professional & Industrial, Science, Engineering & Technology, Education, Outsourcing & Consulting, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Share on Social Networks: